Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9486552 | 0.86 | CA12 (0.50) | HRH3MAPTKMT2AMEN1LMNA | |
| SCHEMBL18642567 | 0.84 | CYP4F2 (0.47) | HRH3MAPTKMT2AMAPK1MEN1 | |
| SCHEMBL52219 | 0.83 | ALDH1A1 (0.52) | HRH3MAPTKMT2AMAPK1MEN1 | |
| SCHEMBL11084824 | 0.82 | KMT2A (0.50) | HRH3MAPTKMT2AMEN1LMNA | |
| SCHEMBL7035447 | 0.81 | HCAR2 (0.49) | MAPTALDH1A1HPGDMAOB | |
| SCHEMBL27787074 | 0.81 | MAPT (0.56) | MAPTKMT2AMAPK1MEN1S1PR4 | |
| SCHEMBL4733 | 0.79 | CYP1A2 (0.55) | MAPTKMT2AMAPK1MEN1S1PR4 | |
| SCHEMBL15270503 | 0.79 | CACNA1B (0.42) | MAPTKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL21801168 | 0.79 | ALDH1A1 (0.47) | KMT2AMAPK1MEN1LMNAALDH1A1 | |
| SCHEMBL5279749 | 0.78 | LMNA (0.53) | MAPTLMNAALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889141-A1 | (R)-3-(4'-(2-(2-METHYLPYRROLIDIN-1-YL)ETHYL)BIPHENYL-4-YL)PROPANOIC ACID AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3309150-B1 | (R)-3-(4'-(2-(2-METHYLPYRROLIDIN-1-YL)ETHYL)BIPHENYL-4-YL)PROPANOIC ACID AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARM INC (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3309150-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| CN-105263914-B | biphenyl-ethyl-pyrrolidine derivatives as histamine H3 receptor modulators for the treatment of cognitive disorders | 艾尼纳制药公司 | 2017-10-27 | — | — | CN | disclosed |
| EP-2943473-B1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARM INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9365511-B2 | Biphenyl-ethyl-pyrrolidine derivatives as histamine H3 receptor modulators for the treatment of cognitive disorders | ARENA PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| CN-105263914-A | Biphenyl-ethyl-pyrrolidine derivatives as histamine H3 receptor modulators for the treatment of cognitive disorders | ARENA PHARM INC | 2016-01-20 | — | — | CN | disclosed |
| US-20150353488-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2943473-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014110103-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353488-A1 | BIPHENYL-ETHYL-PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR MODULATORS FOR THE TREATMENT OF COGNITIVE DISORDERS | HRH3, HRH4, HRH1 | HRH3 1/4885MAPT 237/4885KMT2A 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.